Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 11751 - 11775 of 12870 in total

NGN-401

NGN-401 is a recombinant serotype 9 adeno-associated virus (AAV) encoding an intron encoding a miRNA generating sequence, complementary miRNA binding sites and a full-length human methyl cytosine binding protein 2 (MECP2). Developed by Neurogene Inc., it is being investigated for the treatment of Rett syndrome.
Investigational

FCR001

FCR001 is a somatic cell therapy product containing hematopoietic progenitor cells (HPC), Facilitating Cells (FC), and alpha beta T cells.
Investigational

M1-c6v1

M1-c6v1 is a recombinant oncolytic virus.
Investigational

TSHA-102

TSHA-102 is a recombinant serotype 9 adeno-associated virus encoding a codon-optimized human MECP2 gene.
Investigational

Perenostobart

Perenostobart is an alpha-CD39 IgG4 monoclonal antibody.
Investigational

ECT204

ECT204 is an autologous T-cell therapy whereby T cells are genetically modified to target tumor-specific antigens.
Investigational

IDUA-RTB

RTB-IDUA is a fusion protein of alpha-L-iduronidase (IDUA) and ricin transport subunit B (RTB).
Investigational

ST266

ST266 is an amniotic membrane-derived cellular cytokine solution.
Investigational

VGB-R04

VGB-R04 is an adeno-associated viral vector delivering human FIX Padua gene.
Investigational

AOC-1020

AOC-1020 is an antibody oligonucleotide conjugate, comprised of a human transferrin receptor 1 targeting, effector function null, humanized IgG1 antibody, a MCC maleimide linker, and a double-stranded siRNA oligonucleotide targeting DUX4.
Investigational

CTX130

CTX130 is an allogeneic CRISPR/Cas9-mediated genetically modified CAR T cell therapy targeting CD70 antigen.
Investigational

Allogeneic natural killer cells

Investigational

AVR-RD-05

AVR-RD-05 is a gene therapy comprising genetically modified autologous stem cells transduced ex vivo with a lentiviral vector encoding the human iduronate-2-sulfatase (IDS) enzyme. It is under investigation for the treatment of Hunter Syndrome (Mucopolysaccharidosis Type II, MPSII).
Investigational

OTL-203

OTL-203 is an autologous CD34+ enriched cell therapy that contains hematopoietic stem and progenitor cells transduced ex-vivo using a lentiviral vector encoding alpha-L-iduronidase gene.
Investigational

MaaT013

MaaT013 is an allogeneic fecal microbiota therapy. It is being investigated for the treatment of Graft-Versus-Host Disease.
Investigational

ATIR101

ATIR101 is a haploidentical, naïve cell-enriched T-cell therapy.
Investigational

Allogeneic human pancreatic islets of Langerhans

Investigational

Epidermal Growth Factor Receptor variant III (EGFRvIII) chimeric antigen receptor T cells

Investigational

Autologous CD4+CD25hiFoxP3+regulatory T cells

Investigational

Avoplacel

Avoplacel (PLX-R18) is an allogeneic cell therapy under investigation for the treatment of acute radiation syndrome.
Investigational

Ex vivo expanded autologous human corneal epithelial cells containing stem cells

Holoclar (ex vivo expanded autologous human corneal epithelial cells containing stem cells) is a stem cell therapy used to treat limbal stem cell deficiencies.
Investigational

Ulefnersen

Investigational

Autologous CD34+ hematopoietic stem and progenitor cells expressing adenosine deaminase

Autologous CD34+ hematopoietic stem and progenitor cells expressing adenosine deaminase is an investigational lentiviral gene therapy. It comprises autologous CD34+ hematopoietic stem and progenitor cells (HSPCs) that had been genetically modified ex vivo with EFS-ADA LV.
Investigational

RC88

RC88 is an antibody-drug conjugate comprising a humanized anti-mesothelin monoclonal antibody conjugated to monomethyl auristatin E (MMAE).
Investigational

HLX-58

HLX-58 is an investigational monoclonal antibody targeted against claudin 18.2.
Investigational
Displaying drugs 11751 - 11775 of 12870 in total